Quince Therapeutics (NASDAQ: CRTX)
Quince Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Quince Therapeutics Company Info
Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. Its pipeline consists of COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.
News & Analysis
Why Cortexyme's Stock Is Crashing Today
The FDA's latest move regarding one of this biopharma's investigational drugs all but slams the door shut on its future.
2 Short-Squeeze Candidates That Could Go Parabolic Soon
Cortexyme and Heron Therapeutics are two of the most heavily shorted biopharma stocks right now.
Down 76%: Is Cortexyme Stock a Bargain?
The biotech's stock took a big hit after its lead product candidate flunked a key clinical trial.
Cortexyme's Alzheimer's Drug Fails -- 2 Lessons for Investors
Another new drug candidate for the treatment of Alzheimer's disease failed miserably in a clinical trial.
Here's Why Cortexyme Is Imploding on Wednesday
An Alzheimer's disease trial failure was much worse than the company's relatively upbeat look forward suggests.
Is This Under-the-Radar Stock Set to Succeed in Alzheimer's Disease?
A promising new approach could potentially yield a new drug providing hope for millions of Alzheimer's patients worldwide.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.